Abstract
Serotonin and its various receptors are involved in numerous brain functions and neuropsychiatric disorders. The 5-HT1A family is the best characterized subtype of the fourteen currently known 5-HT receptors. The 5-HT1A receptor is closely involved in the pathogenesis of anxiety, depression, epilepsy and eating disorders and therefore is an important target for drug therapy. The development in the 1980s of molecules specifically targeting this receptor was followed by the rapid development of corresponding PET neuroimaging. Because this receptor represents a crucial target in neuroscience, a large number of radioligands have been developed by academic and industry centers for visualization and quantification, first in living animals and ultimately in humans. After a brief account of some of the structural and functional characteristics of brain 5-HT1A receptors, this review focuses on the main lines of evolutionopened up by preclinical and clinical 5-HT1A PET radiopharmaceuticals, illustrating the potential value of PET for clinical research and drug development.
Keywords: Agonist, antagonist, neurotransmission, positron emission tomography, radiopharmaceutical, 5-HT1A receptor.
Current Medicinal Chemistry
Title:PET Radiotracers for Molecular Imaging of Serotonin 5-HT1A Receptors
Volume: 21 Issue: 1
Author(s): T. Billard, D. Le Bars and L. Zimmer
Affiliation:
Keywords: Agonist, antagonist, neurotransmission, positron emission tomography, radiopharmaceutical, 5-HT1A receptor.
Abstract: Serotonin and its various receptors are involved in numerous brain functions and neuropsychiatric disorders. The 5-HT1A family is the best characterized subtype of the fourteen currently known 5-HT receptors. The 5-HT1A receptor is closely involved in the pathogenesis of anxiety, depression, epilepsy and eating disorders and therefore is an important target for drug therapy. The development in the 1980s of molecules specifically targeting this receptor was followed by the rapid development of corresponding PET neuroimaging. Because this receptor represents a crucial target in neuroscience, a large number of radioligands have been developed by academic and industry centers for visualization and quantification, first in living animals and ultimately in humans. After a brief account of some of the structural and functional characteristics of brain 5-HT1A receptors, this review focuses on the main lines of evolutionopened up by preclinical and clinical 5-HT1A PET radiopharmaceuticals, illustrating the potential value of PET for clinical research and drug development.
Export Options
About this article
Cite this article as:
Billard T., Bars Le D. and Zimmer L., PET Radiotracers for Molecular Imaging of Serotonin 5-HT1A Receptors, Current Medicinal Chemistry 2014; 21 (1) . https://dx.doi.org/10.2174/09298673113209990215
DOI https://dx.doi.org/10.2174/09298673113209990215 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms of Action of Antiepileptic Drugs
Current Topics in Medicinal Chemistry Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction
Current Drug Targets Application of Pharmacophore Models for the Design and Synthesis of New Anticonvulsant Drugs
Mini-Reviews in Medicinal Chemistry <i>In Silico</i> Study Examining New Phenylpropanoids Targets with Antidepressant Activity
Current Drug Targets Pharmacological Benefits of Active Components of Natural Products Against Traumatic Brain Injury - A Review
Current Pharmacogenomics and Personalized Medicine A Review on the Arylpiperazine Derivatives as Potential Therapeutics for the Treatment of Various Neurological Disorders
Current Drug Targets The Importance of Bioactivation in Computer-Guided Drug Repositioning. Why the Parent Drug is Not Always Enough
Current Topics in Medicinal Chemistry Common Issues Among Asthma, Epilepsy, and Schizophrenia: From Inflammation to Ca<sup>2+</sup>/cAMP Signalling
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Classification of Normal and Epileptic EEG Signals Using Adaptive Neuro-Fuzzy Network Based on Time Series Prediction
Neuroscience and Biomedical Engineering (Discontinued) Cardiac ATP-Sensitive Potassium Channels: A Potential Target for an Anti-Ischaemic Pharmacological Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry A Focus on Microfluidics and Nanotechnology Approaches for the Ultra Sensitive Detection of MicroRNA
MicroRNA Preclinical Analyses of the Therapeutic Potential of Allopregnanolone to Promote Neurogenesis In Vitro and In Vivo in Transgenic Mouse Model of Alzheimers Disease
Current Alzheimer Research Subject Index to Volume 1
Medicinal Chemistry Reviews - Online (Discontinued) Polypharmacy in Chronic Neurological Diseases: Multiple Sclerosis, Dementia and Parkinson’s Disease
Current Pharmaceutical Design Diagnostic Boundaries of Autism Disorder Vs Pervasive Developmental Disorder Nos Comparative Observational Study and Literature Review
Current Clinical Pharmacology Kinetic Models for Measuring P-glycoprotein Function at the Blood-Brain Barrier with Positron Emission Tomography
Current Pharmaceutical Design Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?
Current Pharmaceutical Design Cell and Gene Therapies for Refractory Epilepsy
Current Neuropharmacology Uncovering New Pharmacological Targets to Treat Neuropathic Pain by Understanding How the Organism Reacts to Nerve Injury
Current Pharmaceutical Design Melatonin Receptor Agonists: SAR and Applications to the Treatment of Sleep-Wake Disorders
Current Topics in Medicinal Chemistry